.Johnson & Johnson’s deprioritization of its own infectious condition pipeline has claimed another target such as its own dengue infection injection mosnodenvir.Mosnodenvir is actually developed to block communications in between 2 dengue virus proteins. The injection survived J&J’s choice in 2013 to combine its contagious ailment and vaccination functions, which found the likes of a late-stage respiratory syncytial infection program lost coming from the Large Pharma’s pipeline and also an E. coli vaccine sold off to Sanofi.Mosnodenvir has had a bumpy ride in the medical clinic, with J&J canceling one trial due to the effect of COVID-19 on enrollment as well as stopping employment in one more study in 2022.
However the devotion to mosnodenvir seemed to pay off in October 2023, when the vaccination was revealed to generate a dose-dependent antiviral effect on the detectability as well as start of dengue infection serotype 3 in a period 2 test. That information reduce does not seem to have actually sufficed to save mosnodenvir for long, along with the Big Pharma declaring today that it is actually ceasing a follow-up stage 2 area study. The decision is actually related to a “strategic reprioritization of the company’s contagious health conditions R&D profile,” incorporated J&J, which stressed that no safety and security problems had been actually recognized.” Johnson & Johnson will definitely continue to support the fight against dengue by sharing research study results with the medical area in the future,” the pharma said in the release.J&J had been actually acquiring dengue for over a years, consisting of launching a Satellite Center for Global Health Discovery at the Duke-NUS Medical Institution in Singapore in 2022.
The center has actually been paid attention to increasing early-stage revelation research to “address the developing difficulty of flaviviruses” including dengue and also Zika.